Nouvelle déclaration d'incident
No de la demande: 2021-5889
Numéro de référence du titulaire d'homologation: 2021-CA-000075 and 2021-CA-000076
Nom du titulaire (nom légal complet, aucune abbréviation): Wellmark International
Adresse: 100 Stone Road West, Suite 111
Ville: Guelph
État: Ontario
Pays: Canada
Code postal /Zip: N1G 5L3
Incident chez un animal domestique
Pays: CANADA
État: ONTARIO
ARLA No d'homologation 26493 ARLA No de la demande d'homologation EPA No d'homologation.
Nom du produit: Zodiac Powerspot Flea And Tick Control For Dogs Over 14 kg (30 lbs)
ARLA No d'homologation 28743 ARLA No de la demande d'homologation EPA No d'homologation.
Nom du produit: Zodiac Spot On II Flea Control for Cats and Kittens
Oui
Unités: mL
Site: Animal / Usage sur un animal domestique
Propriétaire de l'animal
Dog / Chien
Labrador Retriver and Poodle crossbreed
1
Femme
0.67
21.319
kg
Cutanée
>1 mo <= 6 mos / > 1 mois < = 6 mois
>8 hrs <=24 hrs / > 8 h < = 24 h
Système
Unknown / Inconnu
Non
Non
Unknown/Inconnu
Treatment / Traitement
(p.ex. description des symptômes tels que la fréquence et la gravité
On 07 Mar 2021, the animal owner applied the product topically to the dog for the first time. Approximately 24 hours after application the dog developed itching and hair loss at the application site. At approximately the same time frame, loss of appetite developed. At an unspecified date, the dog developed intermittent vomiting and diarrhea. On 07 Apr 2021, the product was applied topically again to the dog. Clinical signs have persisted. No further information is expected.
Modérée
Assessment: Permethrin, (S)-methoprene, and the inactive ingredients in this product have a wide margin of safety. There is risk of irritation including dermal and GI (if ingested). Dermal irritation may manifest as itching and hair loss. GI irritation may include loss of appetite, vomiting, and diarrhea; however, symptoms are typically mild. Clinical signs due to the product are not expected to persist for this duration. Veterinary examination may have been able to provide further information about the cause of the clinical signs but was not pursued. Other causes should be considered including dietary sensitivities, intermittent dietary indiscretion, stress, and underlying disease. The information contained in this report is based on self-reported statements provided to the registrant during telephone interview(s). These self-reported descriptions of an incident have not been independently verified to be factually correct or complete descriptions of the incident. For that reason, information contained in this report does not and cannot form the basis for a determination of whether the reported clinical effects are causally related to exposure to the product identified in the telephone interviews.
Propriétaire de l'animal
Cat / Chat
Domestic Mediumhair Cat
1
Homme
9
5.443
kg
Cutanée
>1 mo <= 6 mos / > 1 mois < = 6 mois
Unknown / Inconnu
Système
Unknown / Inconnu
Non
Non
Unknown/Inconnu
Treatment / Traitement
(p.ex. description des symptômes tels que la fréquence et la gravité
On 07 Mar 2021, the animal owner applied the product topically on the cat. Since application, the cat has lost an estimated 6 lbs (2.73 kg) and developed anorexia, vomiting, and diarrhea on unspecified dates. On 07 Apr 2021, product was applied topically again to the cat. Clinical signs have persisted. No further information is expected.
Modérée
Assessment: (S)-methoprene and the inactive ingredients in this product have a wide margin of safety. There is risk of GI irritation if ingested; this can include transient loss of appetite, vomiting, and diarrhea; however, symptoms are typically mild and self-limiting. Weight loss and persistence of clinical signs for the duration described in this cat are not expected. Veterinary examination may have been able to provide further information about the cause of the clinical signs but was not pursued. Other causes should be considered including dietary sensitivities, intestinal parasites, and underlying disease. The information contained in this report is based on self-reported statements provided to the registrant during telephone interview(s). These self-reported descriptions of an incident have not been independently verified to be factually correct or complete descriptions of the incident. For that reason, information contained in this report does not and cannot form the basis for a determination of whether the reported clinical effects are causally related to exposure to the product identified in the telephone interviews.